Wednesday, July 25, 2012
Eisai Europe Ltd., of Hatfield, UK, part of Eisai Inc., presented the first clinical data for E2609, a beta-site amyloid precursor protein-cleaving enzyme (BACE) inhibitor, during oral sessions at the Alzheimer's Association International Conference 2012 in Vancouver, British Columbia.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.